Bristol Myers Squibb Showcases Positive Results Of New Phase 3 Study Evaluating Cancer Drug Opdivo | Latest News RSS feed

Bristol Myers Squibb Showcases Positive Results Of New Phase 3 Study Evaluating Cancer Drug Opdivo - Latest News


Bristol Myers Squibb showcases positive results of new Phase 3 study evaluating cancer drug Opdivo

The pharmaceutical giant Bristol Myers Squibb (NYSE:BMY) today revealed positive results from a new study evaluating its lead cancer drug Opdivo. The pharma company’s Phase 3 CheckMate-227 trial evalu... read more

Bristol-Myers shares on the uptick after positive lung cancer trial results and market beating fourth quarter results

Bristol-Myers Squibb Co (NYSE ... after the company reported positive results for its lung cancer trial as well as market-beating fourth quarter numbers. In a statement, the company said the Opdivo an... read more

Bristol-Myers Squibb reports positive results from CheckMate -214 phase 3 study of Opdivo in combo with Yervoy to treat advanced/metastatic RCC

Bristol-Myers Squibb Company announced topline results from the CheckMate -214 ... CheckMate -214 is a phase 3, randomized, open-label study evaluating the combination of Opdivo plus Yervoy versus sun... read more

Looking for another news?


Wired News – Bristol-Myers Squibb’s Phase-3 CheckMate-227 Study Met its Co-Primary Endpoint

On February 05, 2018, the Company declared that the ongoing Phase-3 CheckMate-227 study assessing the combination of Opdivo (nivolumab ... a Breakthrough in Cancer Research Giovanni Caforio, M.D., Cha... read more


Bristol-Myers Squibb (BMY) Q1 2017 Results - Earnings Call Transcript

We shared important new data from our immuno-oncology portfolio at AACR [American Association of Cancer Research], including overall survival data from Study ... 4 molecule in Phase 3 trials. Thank yo... read more

Bristol-Myers Squibb Stock Is Coming Back Slow, but That’s Fine

As the Phase 3 clinical trial ... hope is lost for the drug because the company has other studies in SCLC. Its Phase 2 study that evaluates Opdivo and Yervoy in patients who received platinum-based ch... read more

Bristol-Myers Squibb Reports Third Quarter Financial Results

THIRD QUARTER FINANCIAL RESULTS THIRD QUARTER ... which grew 15%. Opdivo Yervoy Orencia BUSINESS DEVELOPMENT UPDATE NEW SHARE REPURCHASE Bristol-Myers Squibb today announced its Board of Directors app... read more

Bristol-Myers Squibb (BMY) Announces New Data from Opdivo Phase 2 in cHL; ORR was 73% Across Subgroups

In May 2016, the U.S. Food and Drug Administration approved Opdivo for the ... Oncology, Bristol-Myers Squibb, commented, “We continue to expand our Immuno-Oncology science in hematology, and these la... read more

Bristol-Myers Squibb’s new dosing for cancer drug Opdivo gets FDA green light

Bristol-Myers Squibb Co (NYSE:BMY) said the US Food and Drug Administration (FDA) has given the green light for a new dosing schedule for its drug Opdivo, for a number of ... the deputy director of th... read more

5 Reasons Why Investors Should Buy Exelixis (EXEL) in 2019

Exelixis Inc. 's EXEL lead drug ... cancer. The CHMP also gave a positive opinion on the same. Separately, Exelixis has also initiated a phase Ib study (investigator-sponsored) on cabozantinib (in com... read more

Bristol-Myers Squibb announces positive results from phase 3 CheckMate -214 trial of Opdivo plus low-dose Yervoy in patients with advanced RCC

Bristol-Myers Squibb Company announced patient-reported ... Annual Meeting 2018 in Chicago CheckMate -214 is a Phase 3, randomised, open-label study evaluating the combination of Opdivo plus Yervoy ve... read more

Bristol-Myers Squibb Reports Third Quarter Financial Results

Bristol-Myers Squibb Company ... FINANCIAL RESULTS THIRD QUARTER PRODUCT AND PIPELINE UPDATE Product Sales/Business Highlights Worldwide revenues for the third quarter of 2018, compared to the third q... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us